Clinical Trials

72 enrolled

Lymphoma, Mantle-Cell

NCT03328273 2026-04-20

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

69 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT05943496 2025-11-06

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 1 Recruiting

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

35 enrolled

Part1: Advanced B-cell Malignancies

NCT05971251 2025-10-01

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

24 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02157324 2025-08-13

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

21 enrolled 11 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03527147 2022-08-15

PRISM

30 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04836832 2022-06-07

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04564040 2020-12-29

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

20 enrolled

COVID-19, Lymphoma, Mantle-Cell

NCT02211014 2020-07-31

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma